Search: onr:"swepub:oai:gup.ub.gu.se/339358" >
Radiolabeled Somato...
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
-
Eigler, Christopher (author)
-
McDougall, Lisa (author)
-
Bauman, Andreas (author)
-
show more...
-
- Bernhardt, Peter, 1966 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för medicinsk strålningsvetenskap,Institute of Clinical Sciences, Department of Medical Radiation Sciences
-
Hentschel, Michael (author)
-
Blackham, Kristine A. (author)
-
Nicolas, Guillaume (author)
-
Fani, Melpomeni (author)
-
Wild, Damian (author)
-
Cordier, Dominik (author)
-
show less...
-
(creator_code:org_t)
- 2024
- 2024
- English.
-
In: JOURNAL OF NUCLEAR MEDICINE. - 0161-5505 .- 1535-5667. ; 65:4, s. 573-579
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.2...
-
show less...
Abstract
Subject headings
Close
- Our primary aim was to compare the therapeutic index (tumor-to- bone marrow and tumor -to -kidney absorbed -dose ratios) of the new radiolabeled somatostatin receptor antagonist [ 177 Lu]Lu-DOTA-JR11 with the established radiolabeled somatostatin receptor agonist [ 177 Lu]Lu-DOTATOC in the same patients with progressive, standard therapy -refractory meningioma. Methods: In this prospective, singlecenter, open -label phase 0 study (NCT04997317), 6 consecutive patients were included: 3 men and 3 women (mean age, 63.5 y). Patients received 6.9-7.3 GBq (standard injected radioactivity) of [ 177 Lu]Lu-DOTATOC followed by 3.3-4.9 GBq (2 GBq/m 2 3 body surface area) of [ 177 Lu]Lu-DOTA-JR11 at an interval of 10 6 1 wk. In total, 1 [ 177 Lu]Lu-DOTATOC and 2-3 [ 177 Lu]Lu-DOTA-JR11 treatment cycles were performed. Quantitative SPECT/CT was done at approximately 24, 48, and 168 h after injection of both radiopharmaceuticals to calculate meningioma and organ absorbed doses as well as tumor -to -organ absorbed -dose ratios (3 -dimensional segmentation approach for meningioma, kidneys, liver, bone marrow, and spleen). Results: The median of the meningioma absorbed dose of 1 treatment cycle was 3.4 Gy (range, 0.8-10.2 Gy) for [ 177 Lu]Lu-DOTATOC and 11.5 Gy (range, 4.7-22.7 Gy) for [ 177 Lu]Lu-DOTA-JR11. The median bone marrow and kidney absorbed doses after 1 treatment cycle were 0.11 Gy (range, 0.05-0.17 Gy) and 2.7 Gy (range, 1.3- 5.3 Gy) for [ 177 Lu]Lu-DOTATOC and 0.29 Gy (range, 0.16-0.39 Gy) and 3.3 Gy (range, 1.6-5.9 Gy) for [ 177 Lu]Lu-DOTA-JR11, resulting in a 1.4 (range, 0.9-1.9) times higher median tumor-to-bone marrow absorbed -dose ratio and a 2.9 (range, 2.0-4.8) times higher median tumor -to -kidney absorbed -dose ratio with [ 177 Lu]Lu-DOTA-JR11. According to the Common Terminology Criteria for Adverse Events version 5.0, 2 patients developed reversible grade 2 lymphopenia after 1 cycle of [ 177 Lu]Lu-DOTATOC. Afterward, 2 patients developed reversible grade 3 lymphopenia and 1 patient developed reversible grade 3 lymphopenia and neutropenia after 2-3 cycles of [ 177 Lu]Lu- DOTA-JR11. No grade 4 or 5 adverse events were observed at 15 mo or more after the start of therapy. The disease control rate was 83% (95% CI, 53%-100%) at 12 mo or more after inclusion. Conclusion: Treatment with 1 cycle of [ 177 Lu]Lu-DOTA-JR11 showed 2.2-5.7 times higher meningioma absorbed doses and a favorable therapeutic index compared with [ 177 Lu]Lu-DOTATOC after injection of 1.4-2.1 times lower activities. The first efficacy results demonstrated a high disease control rate with an acceptable safety profile in the standard therapy for refractory meningioma patients. Therefore, larger studies with [ 177 Lu]Lu-DOTA-JR11 are warranted in meningioma patients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Keyword
- meningioma
- peptide receptor radionuclide therapy
- DOTA-JR11
- DOTATOC
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Eigler, Christop ...
-
McDougall, Lisa
-
Bauman, Andreas
-
Bernhardt, Peter ...
-
Hentschel, Micha ...
-
Blackham, Kristi ...
-
show more...
-
Nicolas, Guillau ...
-
Fani, Melpomeni
-
Wild, Damian
-
Cordier, Dominik
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Radiology Nuclea ...
- Articles in the publication
-
JOURNAL OF NUCLE ...
- By the university
-
University of Gothenburg